Caicun T. Zhou
Advanced in Lung Metastases

Caicun T. Zhou

No.1800 Yuntai Road, 
Pudong, CN 
Advanced in Lung Metastases
No.1800 Yuntai Road, 
Pudong, CN 
OverviewLocationsClinical Research

Overview

Caicun Zhou practices in Pudong, China. Zhou is rated as an Advanced expert by MediFind in the treatment of Lung Metastases. Their top areas of expertise are Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, EGFR Positive Lung Cancer, Gallbladder Removal, and Lymphadenectomy.

Their clinical research consists of co-authoring 726 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 4 articles in the study of Lung Metastases.

Locations

No.1800 Yuntai Road, Pudong, 200120, China
Other Locations
No. 507, Zheng Min Road, Shanghai, 200433, China
No 1239 Siping Road, Shanghai, 200433, China
Zhengmin Road
Yangpu, 200433, China
Zheng Min Road, Shanghai, 200433, China
No. 1838, Xueyuan West Road, Wenzhou, 325027, China
Tongji University No. 507 Zhengmin Road, Shanghai, 200433, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A Phase III, Randomized, Multi-Center, Open-Label, Comparative Global Study to Determine the Efficacy of Durvalumab or Durvalumab and Tremelimumab in Combination With Platinum-Based Chemotherapy for First-Line Treatment in Patients With Metastatic Non Small-Cell Lung Cancer (NSCLC) (POSEIDON)
A Phase III, Randomized, Multi-Center, Open-Label, Comparative Global Study to Determine the Efficacy of Durvalumab or Durvalumab and Tremelimumab in Combination With Platinum-Based Chemotherapy for First-Line Treatment in Patients With Metastatic Non Small-Cell Lung Cancer (NSCLC) (POSEIDON)
Enrollment Status: Active_not_recruiting
Publish Date: September 25, 2025
Intervention Type: Drug
Study Drugs: Durvalumab, Tremelimumab, Abraxane+Carboplatin, Gemcitabine+Cisplatin, Gemcitabine+Carboplatin, Pemetrexed+Carboplatin, Pemetrexed+Cisplatin
Study Phase: Phase 3
LIBRETTO-431: A Multicenter, Randomized, Open-Label, Phase 3 Trial Comparing Selpercatinib to Platinum-Based and Pemetrexed Therapy With or Without Pembrolizumab as Initial Treatment of Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer
LIBRETTO-431: A Multicenter, Randomized, Open-Label, Phase 3 Trial Comparing Selpercatinib to Platinum-Based and Pemetrexed Therapy With or Without Pembrolizumab as Initial Treatment of Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer
Enrollment Status: Active_not_recruiting
Publish Date: April 20, 2025
Intervention Type: Drug
Study Drugs: Selpercatinib, Carboplatin, Cisplatin, Pemetrexed, Pembrolizumab
Study Phase: Phase 3
A Phase Ib/II Trial of AK112 (PD-1/VEGF Bispecific Antibody) in Patients With Advanced NSCLC
A Phase Ib/II Trial of AK112 (PD-1/VEGF Bispecific Antibody) in Patients With Advanced NSCLC
Enrollment Status: Active_not_recruiting
Publish Date: March 03, 2025
Intervention Type: Drug
Study Drug: AK112
Study Phase: Phase 1/Phase 2
An Open, Single-arm, Multi-center, Phase 2 Clinical Trial of Famitinib Combined With Epidermal Growth Factor Receptor (EGFR) Inhibitor HS-10296 in Patients With Advanced EGFR-mutant Non-Small Cell Lung Cancer (NSCLC)
An Open, Single-arm, Multi-center, Phase 2 Clinical Trial of Famitinib Combined With Epidermal Growth Factor Receptor (EGFR) Inhibitor HS-10296 in Patients With Advanced EGFR-mutant Non-Small Cell Lung Cancer (NSCLC)
Enrollment Status: Unknown
Publish Date: July 07, 2022
Intervention Type: Drug
Study Drugs: Famitinib, HS-10296
Study Phase: Phase 2
Single Arm Phase II Clinical Trial to Investigate the Efficacy and Safety of Apatinib as a Single Agent in Advanced NSCLC Who Failed to at Least Two Lines Systemic Treatment, or Were Not Amendable to Receive the Second-line Standard Therapy
Single Arm Phase II Clinical Trial to Investigate the Efficacy and Safety of Apatinib as a Single Agent in Advanced NSCLC Who Failed to at Least Two Lines Systemic Treatment, or Were Not Amendable to Receive the Second-line Standard Therapy
Enrollment Status: Unknown
Publish Date: August 18, 2017
Intervention Type: Drug
Study Drug: Apatinib Single Agent
Study Phase: Phase 2
View 4 Less Clinical Trials

726 Total Publications

Reply to: "Baseline Brain Metastasis Imbalance in TRUST: Implications for Interpreting Intracranial Efficacy of Taletrectinib" and "Taletrectinib in ROS1 Fusion-Positive Non-Small Cell Lung Cancer: Promising Yet Premature?"
Reply to: "Baseline Brain Metastasis Imbalance in TRUST: Implications for Interpreting Intracranial Efficacy of Taletrectinib" and "Taletrectinib in ROS1 Fusion-Positive Non-Small Cell Lung Cancer: Promising Yet Premature?"
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: August 21, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Zhou's expertise for a condition
ConditionClose
View All 33 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile